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The new chemokine Prokineticin 2 (PROK2) and its receptors (PKR
1
and PKR
2
) have a role in inflammatory pain and
immunomodulation. Here we identified PROK2 as a critical mediator of neuropathic pain in the chronic constriction injury (CCI)
of the sciatic nerve in mice and demonstrated that blocking the prokineticin receptors with two PKR
1
-preferring antagonists (PC1
and PC7) reduces pain and nerve damage. PROK2 mRNA expression was upregulated in the injured nerve since day 3 post injury
(dpi) and in the ipsilateral DRG since 6 dpi. PROK2 protein overexpression was evident in Schwann Cells, infiltrating macrophages
and axons in the peripheral nerve and in the neuronal bodies and some satellite cells in the DRG. Therapeutic treatment of
neuropathic mice with the PKR-antagonist, PC1, impaired the PROK2 upregulation and signalling. This fact, besides alleviating
pain, brought down the burden of proinflammatory cytokines in the damaged nerve and prompted an anti-inflammatory repair
program. Such a treatment also reduced intraneural oedema and axon degeneration as demonstrated by the physiological skin
innervation and thickness conserved in CCI-PC1 mice.These findings suggest that PROK2 plays a crucial role in neuropathic pain
and might represent a novel target of treatment for this disease.
1. Introduction
Identification of the neurobiological processes engaged in the
pathological state that occurs during neuropathic pain may
provide future therapeutic targets. Chemokines and their
receptors are receiving growing interest as modulators of
neuronal plasticity and for their ability to enhance nocicep-
tive transmission under conditions of neuropathic pain [1].
In particular a new family of chemokines, Prokineticin 2
(PROK2) also known as Bv8 and its receptors, two G-protein
coupled receptors, PKR
1
and PKR
2
, emerged as key signals in
immune system and inflammatory diseases [2].
In an animal model of CFA-induced paw inflammation,
we brought evidence that Bv8/PROK2, upregulated in gran-
ulocyte invading the inflamed tissue is a major determinant
in triggering and maintaining inflammatory pain [3]. Neu-
trophils and macrophages are the major sources of PROK2
which is strongly upregulated in inflammatory diseases and
tumours, associated with infiltrating cells [4, 5]. In vivo and in
vitro experiments from our and other groups demonstrated
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potent chemotactic and immunomodulatory activities of the
prokineticins, able to promote the production of proin-
flammatory cytokines from different immune cells and to
modulate T cell function by reducing anti-inflammatory
cytokines production and promotingTh1 responses [5–7].
The typical immune cell response to tissue injury is
largely conserved in the lesioned peripheral nervous sys-
tem: many neutrophils from the circulation invade the area
immediately around the nerve injury site within 8–24 hours
and haematogenous macrophages by 3-4 days post injury,
whereas lymphocyte accumulation in the injured nerve is
delayed by a week or more [8].
We can reasonably presume that PROK2 released by
haematogenous neutrophils invading the damaged nerve
triggers inflammation and contributes to pain.
Besides, in the immune system, PROK2 is also expressed
in discrete nuclei into the brain and is constitutively
expressed, at very low levels, in some DRG neurons also
expressing the vanilloid receptor TRPV1 [9–11]. PROK2binds
PKR
1
and PKR
2
, expressed in small and medium cells of rat
dorsal root ganglia (DRG) and within the superficial laminae
in the spinal dorsal horn [2, 12]. Peripheral administration
of the mammalian PROK2 or its amphibian homologue Bv8
in rodents induced hyperalgesia and allodynia by activat-
ing the PKRs on peripheral nociceptors. In vitro analysis
of functional PKRs on DRG neurons shows a remarkable
overlap in neurons that respond both to Bv8 and capsaicin
(∼90%) and to Bv8 and mustard oil (∼60%) indicating a high
degree of colocalization of functional PKRs with TRPV1 and
TRPA1 channels [13] supporting the possibility that these
receptors contribute to nociceptive signalling. Moreover Bv8,
increasing CGRP and SP expression, induced long-lasting
sensitization of nociceptors resulting in enhanced responses
to evoking stimuli, including Bv8 itself or capsaicin, so
providing a basis for long-lasting hypersensitivity that may
result in conditions of tissue injury [14].
We have recently demonstrated in an animal model of
neuropathic pain, the chronic constriction injury of the sci-
atic nerve (CCI), that 10 days after nerve injury an important
activation of the prokineticin system is evident at peripheral
and central level and that pharmacological blocking of the
prokineticin receptors with the antagonist PC1 abolishes pain
and controls some pathophysiological processes underlying
the neuropathy.
Herewe analysed the time-course of PROK2upregulation
in theDRG and in the injured sciatic nerve ofmice repeatedly
treated with saline or with PC1 for 7 days and demonstrated
that the antihyperalgesic effect of PC1 temporally correlates
with its ability to reduce the neuropathy-induced increase
of PROK2 expression. The recent availability of a new
prokineticin receptor antagonist, PC7, endowed with higher
affinity and selectivity for the PKR1 pushed us to evaluate its
antihyperalgesic effect in comparisonwith that of PC1 [15, 16].
Finally, because CCI of sciatic nerve decreases the density
of paw skin innervation and induces epidermal thinning we
also compared the fibre-density in the dermis and the skin
thickness of the injured paw of mice treated with PC1 or with
saline in comparison with sham operated mice.
2. Methods
2.1. Animal Preparation. Experiments were carried out in
male CD1 mice (25–30 g, Harlan Laboratories, Italy) accord-
ing to protocols approved by the Animal Care and Use
Committee of the Italian Ministry of Health and in
compliance with the IASP and European Community
(E.C.L358/118/12/86) guidelines. All efforts were made to
minimize animal suffering and to reduce the number of
animals used. Animals were housed individually in cages,
under conditions of optimum light, temperature, and humid-
ity (12 : 12 h light/dark cycles, 22± 2∘C, 50–60%)with food and
water ad libitum and acclimatized to the environment for 4-5
days before surgery or pharmacologic treatment.
2.2. Neuropathic Pain Model
2.2.1. Chronic Constriction Injury of the Sciatic Nerve (CCI).
Mononeuropathy was induced by the CCI of the sciatic nerve
[17] in CD1 mice anesthetized by intraperitoneal injection
of ketamine-xylazine (60mg kg−1 + 10mg kg−1). The sciatic
nerve was exposed and three loose ligatures with 4–0 silk
suture thread were made around the nerve with a 1.0–1.5mm
interval between each of them. In sham-operated mice, an
identical dissection was performed on the same side, except
that the sciatic nerve was not tied.
2.3. Nociceptive Behavioural Tests. Behavioural experiments
were carried out by researchers blind to treatments, between
10 am and 2 pm, in a reserved quiet temperature-controlled
room. Mice were habituated to the testing environment and
were handled daily two times for at least three days before
baseline testing.
For testing heat sensitivity, animals were put in plastic
boxes and allowed 30min for habituation before exami-
nation. Heat sensitivity was tested by radiant heat using
Hargreaves apparatus (Ugo Basile, Italy) and expressed as
paw withdrawal latency (PWL). The radiant heat intensity
is adjusted so that basal PWL is between 10 and 12 s with a
cutoff of 20 s to prevent tissue damage. For testing mechan-
ical sensitivity, animals were put in boxes on an elevated
metal mesh floor and allowed 30min for habituation before
examination. Mechanical allodynia was assessed using the
Dynamic Plantar Aesthesiometer (Ugo Basile Italy). The
filament was applied to the skin of the midplantar area of
the hind paw, and it began to exert an increasing upward
force, reaching a maximum of 30 g in 10 s, until the paw
was withdrawn. The paw withdrawal threshold (PWT) was
defined as the force, in grams, at which the mouse withdrew
its paw. PWL and PWT of ipsilateral and contralateral paws
were measured thrice, and the reported value is the mean of
the three evaluations.
2.4. Experimental Design. The PKR antagonists PC1 [16] and
PC7 were injected in mice subcutaneously (s.c., 50 𝜇L for 10 g
body weight) into the flank region of the mouse.
PC1 was administrated chronically at the dose of
150 𝜇g kg−1, s.c., twice a day for 7 days.
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Increasing doses of PC7 (5, 15, and 45𝜇g kg−1) were
administrated s.c. as a single bolus in different groups ofmice,
on day 3 post injury (dpi). Then we chose the highest, more
effective dose (45𝜇g kg−1 s.c.) for the repeated treatment,
twice a day for 4 days.
PC7 (2-(5-(4-fluorobenzyl)-1-(4-methoxybenzyl)-1,4,5,6-
tetrahydro-4,6-dioxo-1,3,5-triazin-2-ylamino)-ethyl)-guan-
idine) is a triazinic compound which displays higher affinity
for the PKR
1
(IC
50
= 56 ± 12 nM, in displacement of 125I-
MIT; IC
50
= 66 ± 12 nM in BRET assay) than for PKR
2
(IC
50
= 5230 ± 700 nM in displacement of 125I-MIT; IC
50
=
4135 ± 600 nM in BRET assay) and is able to antagonize the
Bv8-induced hyperalgesia at doses ten times lower than PC1
[15].
Mice were divided as follows: (i) CCI mice treated with
saline (CCI-saline, 𝑛 = 8); (ii) CCI mice treated with PC1
150 𝜇g kg−1 s.c., twice a day for 7 days or PC7 45𝜇g kg−1 s.c.,
twice a day for 4 days, starting fromday 3 afterCCI (CCI-PC1,
CCI-PC7, 𝑛 = 8/group); (iii) Sham-operated mice treated
with saline (𝑛 = 5); (iv) Sham-operatedmice treatedwith PC1
150 𝜇g kg−1 s.c., twice a day for 7 days or PC7 45𝜇g kg−1 s.c.,
twice a day for 4 days, starting from day 3 after sham surgery
(𝑛 = 5/group) (data not shown).
In sham, CCI-saline, and CCI-PC1 or CCI-PC7 animals,
mechanical allodynia and thermal hyperalgesia were assessed
before and from days 1 to 12 after CCI.
2.5. Biochemical and Histochemical Evaluation
2.5.1. RNA Extraction and Real-Time PCR. Total RNA was
extracted from L4-L5 DRG and sciatic nerve, pooled from
two mice, using the Trizol reagent (Invitrogen, Carlsbad,
CA) according to the manufacturer’s instruction. RNA
yield and purity were determined by spectrophotometry
absorption at 260 and 280 nm. To obtain cDNA, 1 𝜇g of
mRNA underwent to Reverse Transcription (Promega,
Madison,WI).The resulting cDNAwas stored at −20∘C until
used for the further analysis. Messenger RNA expression
was quantitatively measured with quantitative (q) real time
PCR using iCycler Bio-Rad. The reaction was performed in
a 25 𝜇L volume using SensiMix SYBR Green & Fluorescein
kit (Bioline, London, UK). All the measures were performed
in triplicate. The reaction conditions were as follows: 95∘C
for 10min (Polymerase activation), followed by 40 cycles
at 95∘C for 15min, 55–50∘C (temp. depends on the Tm
of primers) for 15 sec and 72∘C for 15 sec. The reaction
mixture without the cDNA was used as control. The
primer sequences used in this study were as follows for
PROK2: forward 5󸀠-CTCGGAAAGTTCCATTTTGG-3󸀠
and reverse 5󸀠-TTCCGGGCCAAGCAAATAAACC-3󸀠,
Glyceralde-hydes-3-phosphate dehydrogenase (GAPDH):
forward 5󸀠-GCCAAGGCTGTGGGCAAGGT-3󸀠 and reverse
5󸀠-TCTCCAGGCGGCACGTCAGA-3󸀠. The Ct value of the
specific gene of interest was normalized to the Ct value
of the endogenous control, GAPDH, and the comparative
Ct method (2-ΔΔCt) was then applied using sham mice
group as calibrator. Results are mean ± SEM of at least 3
experiments.
2.5.2. Cytokine Protein Measurement. Ten days after injury
nerve samples were homogenized in ice-cold phosphate-
buffered saline containing a protease inhibitor cocktail
(Roche Diagnostics, Monza, Italy). IL-6, IL-1𝛽, IL-10 TNF𝛼,
and IL-17 protein contents were determined by a multiplex
enzyme-linked immunosorbent assay using ultrasensitive
murine ELISA (Milliplex, Millipore, Vimodrone, Italy). A
standard curve ranging on average from 0.15 pg/mL to
3700 pg/mL was prepared and then fitted by Bio-Plex Man-
ager software.
2.5.3. Immunofluorescence. At 10 dpi DRG, sciatic nerve and
plantar skin were dissected from transcardially perfused
(PBS followed by 4% paraformaldehyde) mice embedded in
cryostat medium and frozen. Serial sections (20 𝜇m)were cut
using a cryostat and thaw-mounted onto glass slides. Prior to
immunofluorescence staining all sections were blocked with
3% normal donkey serum (serum source was the same as
the secondary antibody producing species), containing 0.3%
Triton X-100 for 1 h at room temperature. Then the sections
were incubated at 4∘C overnight with the following primary
antibodies diluted in PBS-0.3% Triton X-100: 1/200 rabbit
polyclonal anti-PROK2 (AbCam, Cambridge, UK), 1/400
mouse polyclonal anti-glial fibrillary acidic protein (GFAP)
(Immunological Sciences, Italy), 1/100 rat monoclonal anti-
CD11b (BD Pharmigen, Italy), 1/300 mouse monoclonal anti-
S100𝛽 (Sigma-Aldrich, Milano, Italy), 1/200 mouse mon-
oclonal [NF-200] to hypophosphorylated neurofilament H
(AbCam, Cambridge, UK), and 1/300 goat polyclonal anti-
CGRP (AbCam, Cambridge, UK). The sections were then
incubated for 2 h at room temperature in 1 : 200 anti-
species IgG antibodies coupled to Alexa Fluor-488 or 555
(Immunological Sciences, Italy). Nuclei were stained with
DAPI 1/500. The stained sections were examined at confocal
laser scanning microscope (Leica SP5, Leica Microsystems,
Germany). Immunofluorescence intensity or immunoreac-
tive area was measured in five fields (300 𝜇m2) for every
section in at least 10 sections for every experimental group
(http://imagej.nih.gov/ij/index.html free software).
The specificity of the anti-PROK2 antibody was tested
preadsorbing it with the protein PROK2 (500 ng) overnight
at 4∘C before incubation with tissue.
2.5.4. Plantar Skin Histology. At 10 dpi the skin samples from
plantar surface of sham, CCI-saline, and CCI-PC1 mice were
embedded in paraffin in a correct orientation, so that they
could be sectioned perpendicular to the skin surface.Plantar
skin sections (5 𝜇m) were deparaffinized, hydrated and
stained by a brief immersion in Mayer’s hematoxylin and
eosin, followed by a brief dehydration in ethanol and xylene,
andmounted with DPXmountingmedium (Sigma, St. Louis,
MO, USA). Sections were photographed at 20xmagnification
(Olympus U-CMAD3, Japan). Epidermal thickness, indi-
cated as the distance between the dermoepidermal junction
and the top of the outer most granular layer, was evaluated
in three sections per tissue sample. On each image 4-5
measurements were made along the strip of epidermis to
assess the average thickness. Data were expressed as mean ±
SEM.
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2.6. Evans Blue Assay. The permeability of blood nerve
barrier (BNB) was determined by Evans Blue dye extrava-
sation in sciatic nerve, 3 dpi. Evans Blue dye (4%, 5mL/kg)
was injected into the tail vein of anaesthetized mice. After
30min animals were perfused with PBS. The sciatic nerves
were removed and incubated in 1mL formamide (Sigma-
Aldrich) at 60∘C for 24 h. Evan’s Blue concentration was
determined using a spectrophotometer (ShimadzuUV-160A)
at a wavelength of 620 nm.
The data are expressed as 𝜇g of Evans Blue per g of tissue.
2.7. Statistic. Results are expressed as mean ± SEM. When
appropriate, One-way ANOVA followed by Tukey’s posttest
for multiple comparisons or Two-way ANOVA followed
by Bonferroni’s posttest repeated measures were performed
using GraphPad Prism 5 for Windows version 5.4. Differ-
ences were considered significant at ∗∘𝑃 < 0.05, ∗∗∘∘𝑃 < 0.01,
and ∗∗∗∘∘∘𝑃 < 0.001.
3. Results and Discussion
3.1. Nociceptive Behavioural Results. Figure 1 shows that,
since day 3 after CCI, thermal and mechanical nociceptive
thresholds decrease of 40%–50% in the ipsilateral compared
to contralateral hind paw. Both allodynia and thermal hyper-
algesia were observed at the following postlesion time points:
3, 6, 10, and 12 days.
Therapeutic treatment of CCI mice with PC1 from day
3 (when hyperalgesia peaks) to day 9 post injury (dpi)
abolished thermal and also mechanical hyperalgesia so that
from 6 up to 12 dpi PWL and PWT of injured paw did not
differ from those of sham mice (Figure 1).
Availability of a new Bv8 antagonist, named PC7, able
to antagonize the Bv8-induced hyperalgesia at doses ten
times lower than PC1 and endowed with higher selectivity
for the PKR
1
[15] pushed us to evaluate its efficacy in this
neuropathic pain model. Single bolus s.c. injections of PC7 at
3 dpi, when thermal andmechanical hyperalgesia reached full
development, dose-dependently reduced pain (Figures 2(a),
and 2(b)) at doses (5, 15, and 45 𝜇g kg−1) about 3 times lower
than the doses of PC1 which we have already demonstrated
able to reduce/abolish the CCI-induced thermal and tactile
hyperalgesia [16]. The antihyperalgesic effect of the highest
dose (45 𝜇g kg−1, s.c.) peaked in 15 minutes and lasted for
3 h. Then we treated the mice with the highest dose (45 𝜇g
kg−1, s.c) two times/day for only four days (3 to 6 dpi) and
measured the nociceptive threshold every morning up to
12 dpi. Like PC1, PC7-treatment abolished the nerve-injury-
induced thermal and mechanical hyperalgesia within 2 days
and continued to confer protection over the observation
period, up to 12 dpi (Figures 2(c), and 2(d)). Repeated
administration of PC1 or PC7 did not change the thermal and
mechanical nociceptive thresholds of sham mice (data not
shown).
The prompt reversal of pain after acute administration
depends on blocking the PKRs on peripheral sensory neu-
rons. Indeed, as we have already demonstrated both receptors
mediate the Bv8/PROK2-induced decrease of nociceptive
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Figure 1: Repeated systemic injections of PC1 (150 𝜇g kg−1, twice a
day) from 3 to 9 dpi reverted the CCI-induced thermal hyperalgesia
(a) and mechanical allodynia (b) in two days. The antihyperalgesic
effect lasted after treatment withdrawal, for all the observation
period. Data representmeans± SEMof 6–9mice. Two-wayANOVA
was used for statistical evaluation, followed by Bonferroni’s test.
∘∘∘
𝑃 < 0.001 CCI-PC1 versus CCI-saline mice.
threshold: PKR
1
in cooperation with TRPV1 is the recep-
tor mainly responsible for thermal hyperalgesia and PKR
2
mainly contributes to mechanical allodynia [16].
3.2. PROK2 mRNA Time-Course in DRG and Sciatic Nerve.
In a previous paper we have already demonstrated that at
10 dpi PROK2 was overexpressed in the periphery and in the
spinal cord of neuropathic mice but was maintained close to
physiological levels in neuropathic mice treated with PC1 for
7 days.
Here we studied in detail the time-course (from day 1 to
17) of injury-induced PROK2 mRNA overexpression in the
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Figure 2: Antihyperalgesic effect of PC7. A single bolus s.c. injection of PC7 (5, 15, and 45 𝜇g kg−1) on day 3 after CCI dose-dependently
reverted the established CCI-induced thermal hyperalgesia (a) and mechanical allodynia (b). The highest dose of PC7 (45 𝜇g kg−1) abolished
hyperalgesia for about 3 h. Repeated systemic injections of PC7 (45 𝜇g kg−1, twice a day) from 3 to 7 dpi significantly reduced the CCI-induced
thermal hyperalgesia (c) and mechanical allodynia (d) for all the observation period. Data represent means ± SEM of 5 mice. Two-way
ANOVA was used for statistical evaluation, followed by Bonferroni’s test. ∘𝑃 < 0.05; ∘∘𝑃 < 0.01; ∘∘∘𝑃 < 0.001 CCI-PC7 versus CCI-saline
mice.
peripheral nervous system. PROK2 levels in the peripheral
nervous system of healthy animals were negligible. RT-PCR
gave 33.49±0.09Ct in the sciatic nerve and 33.97±0.41Ct in
the DRG. However, as reported in Figure 3(a), in the sciatic
nerve the PROK2 expression was significantly increased at
3 dpi (about 3-fold) when thermal and mechanical hyperal-
gesia were already evident, reached its maximal expression
(8 fold) at 10 dpi, and then started to decrease up to 17 dpi.
In the ipsilateral L4-6 DRG it started to increase later, at
6 dpi, and showed a constant tendency to increase up to 17 dpi
(Figure 3(b)). The fact that PROK2 overexpression in DRG
was delayed and lasted longer than in sciatic nerve indicates
the presence of a flow of activation that, starting from the
periphery, moves towards the centre. The early increase of
PROK2 expression in the injured nerve is probably associated
with neutrophils and Schwann Cells (SC) which express
PROK2 (see afterwards) and which begin to dedifferentiate
and to proliferate within 48 h of injury reaching the peak
of proliferation around 4 dpi [8]. Given that PROK2 pro-
motes survival and migration of granulocytic and monocytic
lineages, the injury induced increase of PROK2 in the nerve
might activate PKR
1
expressed on different immune cells thus
promoting the further recruitment of new ones. Infiltration
of macrophages rich in PROK2 together with the subsequent
6 BioMed Research International
0
5
10
Days after CCI
3 6 10 17
 P
RO
K2
 m
RN
A
 ex
pr
es
sio
n
Sham
CCI-saline
CCI-PC1
∗∗∗
∗∗∗
∗ ∗
∘∘∘
∘∘∘
∘
(a)
0
5
10
Days after CCI
6 173 10
PR
O
K2
 m
RN
A
 ex
pr
es
sio
n
Sham
CCI-saline
CCI-PC1
∘∘∘ ∘∘∘
∘∘∘
∗∗∗
∗∗∗
∗∗∗
(b)
Figure 3: Time-course of PROK2 mRNA expression in injured sciatic nerve and ipsilateral DRG of CCI-saline mice and CCI-PC1 mice.
PROK2 levels in the peripheral nervous system of healthy animals were negligible (33.49 ± 0.09 Ct in sciatic nerve, 33.97 ± 0.41 Ct in DRG).
In the sciatic nerve (a) PROK2 expression was significantly increased at 3 dpi, reached its maximal expression at 10 dpi, and then started to
decrease up to 17 dpi. In the ipsilateral L 4–6 DRGs (b) PROK2 mRNA was significantly increased at 6 dpi and showed a constant tendency
to increase up to 17 dpi. Data are mean ± SEM of 5 animals. One-way ANOVA was used for statistical evaluation, followed by Tukey test for
multiple comparisons. ∗𝑃 < 0.05, ∗∗∗𝑃 < 0.001 CCI-saline versus sham; ∘𝑃 < 0.05 CCI-PC1 versus CCI-saline.
PROK2 upregulation in the nerve (see afterwards) answers
for the further increase in PROK2 mRNA that gets to
maximum level in the nerve at 10 dpi. The PROK2 mRNA
levels in the sciatic nerve and DRG of PC1 treated mice did
not differ from the PROK2 levels of sham animals at any time
points.
Then we performed a detailed analysis of the cellular
localization and modulation of PROK2 in the peripheral
nervous system at 10 dpi, the time of its maximal expression.
3.3. PROK2 Localization in Dorsal Root Ganglia. At
10 dpi, immunohistochemical analysis demonstrated a
strong increase of immunoreactive protein PROK2 in the
ipsilateral DRG of neuropathic mice respect to DRG of
sham-operated mice, where the PROK2 signal was very
faint (Figures 4(a), and 4(b)). Moreover in the ipsilateral
DRG, the number of PROK2 positive neurons was frankly
increased respect to sham mice, with immunofluorescence
distributed in the whole cell body. PROK2 showed a
cytoplasmatic vesicular pattern, characteristic of proteins
that are packaged and transported/released. PROK2
fluorescence was also increased in some GFAP positive cells
around the neuronal bodies (Figure 4, arrows) indicating
that PROK2 is expressed also by satellite cells. In PC1-treated
mice PROK2 signal was significantly reduced mainly in
neurons, compared to the saline-treated neuropathic mice
(Figure 4(c)) as demonstrated by comparison of PROK2
immunofluorescence intensity in sham, CCI-saline, and
CCI-PC1 mice (Figure 4(d)).
3.4. PROK2 Localization in Sciatic Nerve. In the sciatic nerve
of sham-operated mice PROK2 immunoreactivity (green)
was very faint and appeared colocalized inGFAPpositive cells
(yellow) (Figure 5(a)) whereas on 10 dpi a heavy infiltration of
PROK2-positive cells (green colour, Figure 5(b)) was evident
in the neuroma in the immediate proximity of the injury.The
PROK2 positive cells are macrophages as demonstrated, in
Figure 5(d), by double staining (yellow) with themacrophage
marker CD11b (red). But they are also activated Schwann cells
(SC) GFAP-positive (Figure 5(e)) and myelinating SC iden-
tified by S100𝛽 (Figure 5(f)). One week repeated treatment
with the PKR-antagonist dramatically reduced the PROK2
immunofluorescence but not the number of infiltrating
cells (Figure 5(c)). However, comparing the percent CD11b-,
GFAP-, and S100𝛽-positive area in injured nerve from saline-
treated mice with respect to injured nerve from PC1-treated
mice showed that the %GFAP-positive area was significantly
reduced by PC1-treatment suggesting a lesser activation of
SC whereas the pharmacological treatment had not affected
macrophage recruitment nor myelinating SC (Figures 6(a)–
6(i)). Lesser activation of SC may be a proof of lesser axonal
degeneration in PC1-treated animals.
In longitudinal sections of the sciatic nerve (Figures 7,
8, and 9), immunofluorescence staining of nerve proximal
and distal to the lesion demonstrated a dramatic increase
of PROK2 signal (green) in the endoneurial space. The
green signal was distributed in elongated structures, probably
axons, and appeared more intense in the proximal than distal
nerve suggesting that it is transported fromDRG towards the
peripheral terminals.
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Figure 4: Representative sections of mouse L4-L5 ipsilateral DRG, at 10 dpi, from sham (a), CCI-saline (b), and CCI-PC1 (c) mice.
Immunofluorescence double-staining of PROK2 (green)withGFAP (marker for satellite cells, red). Cell nuclei were counterstainedwithDAPI
(blue fluorescence). In DRG of sham-operated mice the PROK2 signal was very faint, localized only along cell membrane of some neurons,
mainly small sized (arrowheads), and in few GFAP+ satellite cells (arrow) (a). In neurons of CCI-saline mice, PROK2 immunofluorescence
was significantly increased and showed a vesicular cytoplasmatic patternwhich is dense in proximity of the neuronalmembrane (arrowheads).
The number of PROK2+ satellite cells is increased (arrows). PROK2 signal in CCI-PC1mice was comparable with that of shammice (c). Scale
bar, 30 𝜇m. (d) Evaluation of PROK2 fluorescence intensity. One-way ANOVA was used for statistical evaluation, followed by Tukey test for
multiple comparisons ∗∗∗𝑃 < 0.001 CCI-saline versus sham mice; ∘∘∘𝑃 < 0.001 CCI-PC1 versus CCI-saline mice.
Double staining with GFAP demonstrated PROK2 in
SC (yellow) scattered between fibres in the proximal nerve
(Figure 7(a)) and mainly aligned to form a band in the
distal nerve (Figure 7(c)), probably the bands of Bu¨ngner,
which provide a supportive substrate and growth factors
for regenerating axons [18]. In the injured sciatic nerve
from PC1-treated mice the PROK2 immunofluorescence was
dramatically reduced both in the fibres and in the SC (Figures
7(b) and 7(d)).
In the distal but not proximal injured nerve we found
large CD11b+ cellsmany of which are also positive for PROK2
in neuropathic mice (Figure 7(e)), whereas the CD11b+ cells
did not show any costaining with PROK2 in PC1-treated neu-
ropathic mice (Figure 7(f)), confirming that PC1 treatment
prevented the PROK2 upregulation also in macrophages.
In CCI-mice double-stained with NF200, which rec-
ognizes the heavy chain of neurofilaments in myelinated
fibres [19], strong PROK2-green signal was localized between
NF200 positive fibres. This staining was not found in the
nerve of PC1-treated mice (Figures 8(a)–8(e)).
Double staining with CGRP, which recognizes peptider-
gic neurons, demonstrated the presence of PROK2 protein in
CGRP-immunoreactive (IR) fibres in proximal and in distal
injured nerve of saline treated mice. PROK2 signal was very
low in injured nerve of PC1-treated mice (Figures 9(a)–9(e)).
These analyses clearly demonstrate that during nerve
injury a large amount of PROK2 is expressed by almost all
cell types present in the nerve, both resident and infiltrating,
for a sustained period of time.
Bv8/PROK2-PKRs are therefore ligand/receptor pairs in
the regulation of pain sensation [20, 21] and the transient
receptor potential vanilloid 1 (TRPV1) is a critical molecular
link between PKRs and primary sensory neuron activation
[13]. TRPV1 is upregulated by nerve injury and TRPV1, as
well as the PKRs, is also expressed in sensory nerve axons
of peripheral nerves, not only at peripheral terminal [16, 22].
It is quite possible, therefore, that axonal TRPV1, just like
peripheral terminal TRPV1, may also become sensitized by
the persistent activation of the PKRs due to the presence of
PROK2. PC1/PC7 reducing PROK2 availability and blocking
the PKRs prevents nociceptor sensitization.
3.5. Cytokines in the Sciatic Nerve. Injury of the peripheral
nervous system induces immune and nonimmune cells to
produce cytokines at and distal to lesion sites. Proinflam-
matory cytokines contribute to axonal damage and they also
stimulate spontaneous nociceptor activity [23].
We and others have analyzed the time-course of the
production of pro- and anti-inflammatory cytokines in the
nervous tissues after sciatic nerve injury [24, 25]. Schwann
cells, resident activated macrophages, and fibroblast rapidly
upregulate the expression and production of TNF𝛼, IL-1𝛽,
and G-CSF which are detected between 5 and 10 h after
injury. Inflammatory cytokines and chemokines advance the
recruitment of blood-borne macrophages that begins 2 to
3 days after the injury concomitantly with production and
secretion of IL-6 and IL-10 proteins. IL-17 positive cells have
been demonstrated in the endoneurium of the injured sciatic
nerve 7 days following CCI [26] and IL-17 has been demon-
strated to have a role in later phases of the processes of the
development of neuropathic pain [27]. As shown in Table 1,
in our experimental setting, at 10 dpi, we found still high
levels of IL-1𝛽, IL-6, and IL-17 but they were reduced at levels
nonsignificantly different from basal in animals treated with
the PKR antagonist. Moreover the pharmacological treat-
ment increased the levels of the anti-inflammatory cytokines
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Figure 5: Representative images of sciatic nerve section in the immediate proximity of the injury, from sham (a), CCI-saline (b), and CCI-
PC1 (c) mice at 10 dpi. (a) In the sciatic nerve of sham-operated mice PROK2 immunoreactivity (green) was very faint and colocalized with
GFAP (red) in elongated SC. (b) A heavy infiltration of PROK2-positive cells (green) was evident in the nerve from CCI-saline mice. (c) PC1
treatment significantly reduced the PROK2 immunoreactivity in these cells. Scale bar, 30𝜇m. Immunofluorescence double-staining showing
colocalization (yellow, arrowheads) of PROK2 (green) with CD11b (macrophage marker, red) (d), GFAP (Schwann cell marker, red) (e), and
S100𝛽 (Schwann cell marker, red) (f) in the immediate proximity of the injury in the sciatic nerve of CCI-saline mice. (d󸀠) CD11b (red), (e󸀠)
GFAP (red), (f󸀠) S100𝛽 (red), and (d󸀠󸀠, e󸀠󸀠, f󸀠󸀠) PROK2 (green) shown in single channels. Scale bar, 10 𝜇m. Cell nuclei were counterstained with
DAPI (blue fluorescence).
Table 1: Sciatic nerve cytokine levels ten days after CCI and after seven-day PC-1 treatment.
Cytokine
pg/mg protein Sham CCI-Saline CCI-PC1
TNF𝛼 0 6.4 ± 3.1 0.97 ± 1.33∘
IL-1𝛽 64.26 ± 13.59 557.7 ± 121∗∗ 222.5 ± 110.31∘
IL-6 4.92 ± 3.37 13.35 ± 6.15∗ 4.30 ± 2.88∘
IL-17 0.97 ± 0.13 13.9 ± 1∗ 3.1 ± 1.8∘
IL-10 556.8 ± 50.35 326.8 ± 8.99∗ 867.3 ± 95.2∘∘∘
Values are means ± SD of 5 nerves.
∗
𝑃 < 0.05; ∗∗𝑃 < 0.01 CCI-Saline versus Sham; ∘𝑃 < 0.05, ∘∘∘𝑃 < 0.001 CCI-PC1 versus CCI-Saline.
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Figure 6: Immunostaining of activated macrophages (CD11b+, red), S100𝛽+ SC (red), and GFAP+ SC (red) in the neuroma from CCI-saline
and CCI-PC1mice ((a)–(h)). Repeated treatment with the PKR-antagonist significantly reduced the GFAP+ activated SC (i) but did not affect
S100𝛽+ SC or macrophage infiltration ((c), (f)).
IL-10, reestablishing the physiological balance between pro-
and anti-inflammatory cytokines and bringing the innate-
immune response to conclusion far earlier thanwhat happens
during spontaneous course of Wallerian degeneration. These
data suggest that PC1 is able to direct the polarization of
recruitedmacrophages towards theM2phenotype [28]which
is involved in tissue repair.
3.6. Skin Innervation and Thickness. CCI of the sciatic nerve
produces partial denervation of the paw skin and results
in a significant reduction in epidermal thickness of the
plantar surface of the injured paw [29]. Accordingly, in
our setting, epidermis of the paw ipsilateral to the injured
nerve was significantly thinner than that of contralateral paw
(32.1 ± 2.1 𝜇m versus 44.1 ± 3.3 𝜇m, 𝑃 < 0.05) at 10 dpi.
The overall organization of denervated epidermis preserved
normal histological organization, but the vital layers showed
reduction in thickness. PC1 treatment prevented the thinning
of the plantar skin (57.3 ± 2.4 𝜇m) (Figure 10).
According to data reported by Peleshok and Ribeiro-
da-Silva [30] immunohistochemical staining for CGRP and
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Figure 7: Representative images of CCI-induced upregulation of PROK2 in the longitudinally sliced sciatic nerve proximal and distal to the
lesion. At 10 dpi a dramatic increase of PROK2 signal (green, a and c) in fibres and in GFAP+ structures (yellow) was evident both proximal
and distal to the lesion.The PROK2 signal was dramatically reduced in the nerve fromCCI-PC1mice (green, b and d). Scale bar: 30𝜇m.High-
magnification images showed macrophages that infiltrate the nerve distal to the lesion (scale bar: 10 𝜇m). (e) Double immunofluorescence
labelling for PROK2 (green) and CD11b (red) showing that in the CCI-saline mice the infiltrating macrophages contain PROK2 (yellow). (f)
PROK2 signal was absent in macrophages infiltrating the nerve from CCI-PC1 mice. (e󸀠, f󸀠) CD11b (red), and (e󸀠󸀠, f󸀠󸀠) PROK2 (green) shown
in single channels. Cell nuclei were counterstained with DAPI (blue fluorescence).
NF200 of plantar skin of neuropathic mice at 10 dpi demon-
strated a virtual absence of CGRP-IR fibres and a dramatic
reduction of NF100-IR fibres (Figures 11(b) and 11(e)) in
comparison with sham-operated mice (Figures 11(a) and
11(d)). Conversely in PC1-treated neuropathic mice a thick
network of CGRP-IR fibres of higher density than that of
sham animals was seen and the NF200 innervation pattern
resembled that seen in the sham-operated mice also if the
signal appeared less intense (Figures 11(c) and 11(f)). These
results indicate that repeated treatmentwith PKR
1
-antagonist
protected from axonal damage.
3.7. Intraneural Oedema and Blood Nerve Barrier Permeabi-
lization. The constrictive ligatures around the sciatic nerve
evoke intraneural edema that causes the nerve to strangu-
late beneath the ligatures and induce axotomy of mostly
large-diameter myelinated axons, sparing mainly C-fibres.
Peripheral nerve injury and C-fibres activation increase the
blood-nerve barrier (BNB) permeabilization in 24–48 h [31].
The PKRs are expressed also on endothelial cells where they
may regulate cell proliferation and vascular leakage [32].
Because we know that systemic injection of PC1 rapidly
reduced oedema of the inflamed paw [3] here we decided to
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Figure 8: Confocal images of representative sections of longitudinally sliced sciatic nerve, proximal and distal to the lesion, immunostained
for PROK2 (green) and NF200 (red) from sham-operated, CCI-saline and CCI-PC1 mice at 10 dpi. Scale bar: 30 𝜇m. PROK2-green signal
was localized between NF200 positive fibers in CCI-saline mice but was not found in the nerve from CCI-PC1 mice.
verify if the treatment with PKR-antagonist might reduce the
blood-nerve barrier permealization consequent to periph-
eral nerve injury. As demonstrated by Figure 12, the Evans
Blue dye extravasation in the sciatic nerve is dramatically
reduced already after 2-day-treatment of neuropathic mice
with 150𝜇g kg−1 of PC1. Plasma extravasation depends on
activation of endothelial PKR
2
[32]. PC1, at the doses here
used in therapeutic schedule, may block also PKR
2
so
exerting further beneficial effect in maintaining the blood-
nerve barrier function and in reducing oedema.
Reduced intraneural oedema may result in sparing more
axons from degeneration as demonstrated by the fact that
skin innervation and skin thickness of neuropathic mice
treated with the PKR-antagonist look like that of sham mice.
4. Conclusions
The results that we here present support an important role
for PROK2 in the pathogenesis of neuroinflammation and
neuropathic pain. In support of this hypothesis, we show
that blocking the prokineticin receptors with two PKR
1
-
preferring antagonists reduced pain and nerve damage. The
major finding of this study is that the nerve damage induces
an important PROK2-increase in resident and infiltrating
cells but also in the sensory neurons and that impairment
of PROK2 production is linked to amelioration of pathology
indicating PROK2 as precocious determinant in the process
of neuroinflammation.
A few studies focused on the mechanisms involved
in regulating the expression of PROK2 in myeloid cells
demonstrated that PROK2-upregulation occurs through G-
CSF-induced activation of STAT3 that binds the enhancer
site of its promoter [33, 34], IL-6 cooperates with G-CSF to
increase the expression of Bv8/PROK2 gene in neutrophils
[35], andmoreover Bv8 itself activates STAT3 [36].Therefore,
PROK2 is involved in a self-perpetuating cycle because it also
increases its own production as a result of PKR
1
activation
[3].
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Figure 9: Confocal images of representative sections of longitudinally sliced sciatic nerve proximal and distal to the lesion, immunostained
for PROK2 (green) and CGRP (red) from sham-operated, CCI-saline and CCI-PC1 mice at 10 dpi. Scale bar: 30 𝜇m.
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Figure 10: (a) Histological examination of the plantar skin from sham, CCI-saline, and CCI-PC1 mice stained with hematoxylin-eosin at
10 dpi. (b) Quantification of epidermal thickness of the sham, CCI/saline, and CCI/PC1 mice (3 section/animal). Data are expressed as mean
± SEM of 4-5 animals. One-way ANOVA was used for statistical evaluation, followed by Tukey test for multiple comparisons: ∗𝑃 < 0.05;
∘∘∘
𝑃 < 0.001.
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Figure 11: Confocal images of representative skin sections immunostained for CGRP and NF200 from sham-operated, CCI-saline, and CCI-
PC1mice at 10 dpi. (a) In sham-operatedmice theCGRPpositive fibers were distributed along the dermoepidermal junction. (b) InCCI-saline
mice the CGRP positive fibers were absent. (c) In CCI-PC1 mice the CGRP positive fibers were present in dermis. (d) In sham-operated mice
the NF200 positive fibers were distributed along the dermoepidermal junction and in dermis. (e) In CCI-saline mice very fewNF200 positive
fibers were observed. (f) In CCI-PC1 mice the NF200 positive fibers were present in dermis. Dashed line represents the dermoepidermal
junction. Scale bar 20 𝜇m.
Intracellular pathway regulating the expression of PROK2
in neurons has not yet been clarified but it may be well-
funded to imagine a mechanism like that described in
myeloid cells. Indeed, STAT3 activation by G-CSF, IL-6, and
IL-1𝛽 signalling was recently demonstrated in DRG neurons
[37, 38]. Receptors and signalling mediators of G-CSF are
functionally expressed on sensory neurons also containing
TRPV1 [37], some of which constitutively express PROK2
mRNA [11], and G-CSF rapidly produced phosphorylation
of STAT3 in cultured DRG neurons [39]. Hence it is likely
that the cytokines released early during the Wallerian-
degeneration trigger synthesis of PROK2 in the sensitive
neurons. STAT3 is required for T helper type 17 (Th17)
generation [40] and Ferrara’s group recently demonstrated
that IL-17 indirectly contributes to recruitment of Bv8-
positive granulocytes in tissues infiltrated by Th17 cells [41].
Interestingly, we also demonstrated that switching off the
PROK2 production and signalling significantly decreases the
burden of proinflammatory cytokines in the lesioned nerve
and prompts an anti-inflammatory repair program.
Taken together, these considerations indicate that avail-
ability of molecules, like these PKR
1
-preferring antagonists,
which in addition to direct modulating nociceptor excitabil-
ity also control the PROK2 synthesis and release, improves
the efficacy in reducing neuroinflammation and neuropathic
pain.
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Figure 12: Evans Blue extravasationwasmeasured at 3 dpi in injured
and contralateral sciatic nerves. A significant increase in Evans Blue
accumulation was evident in the injured nerve. The level of Evans
Blue in the contralateral nerve was not significantly different from
the level found in sham animals. Evans blue extravasation in the
sciatic nerves of mice treated with PC1 (150𝜇gKg−1, twice/day, at 1
and 2 dpi) did not differ from shammice.Data are expressed asmean
± SEM of 4-5 animals. One-way ANOVA was used for statistical
evaluation, followed by Tukey test for multiple comparisons: ∗∗∗𝑃 <
0.001 CCI-saline versus sham mice; ∘∘∘𝑃 < 0.001 CCI-PC1 versus
CCI-saline mice.
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